Literature DB >> 16612597

Effects of interferon gamma on native human acute myelogenous leukaemia cells.

Elisabeth Ersvaer1, Jørn Skavland, Elling Ulvestad, Bjørn Tore Gjertsen, Øystein Bruserud.   

Abstract

T cell targeting immunotherapy is now considered a possible strategy in acute myelogenous leukaemia (AML), and IFNgamma release may then contribute to the antileukaemic effects. We investigated the effects of IFNgamma on native human AML cells. Normal T cells could be activated to release IFNgamma in the presence of AML cells. Furthermore, high levels of CD119 (IFNgamma receptor alpha chain) expression were observed for all 39 patients examined. Receptor expression was decreased after exposure to exogenous IFNgamma, and receptor ligation caused Stat1 phosphorylation but no phosphorylation of the alternative messengers Erk1/2. The effect of exogenous IFNgamma on AML blast proliferation was dependent on the local cytokine network and IFNgamma (1) inhibited proliferation in the presence of exogenous IL1beta, GM-CSF, G-CSF and SCF; (2) had divergent effects in the presence of IL3 and Flt3 (65 patients examined); (3) inhibited proliferation in the presence of endothelial cells but had divergent effects in the presence of fibroblasts, osteoblasts and normal stromal cells (65 patients examined). IFNgamma increased stress-induced (spontaneous) in vitro apoptosis as well as cytarabine-induced apoptosis only for a subset of patients. Furthermore, IFNgamma decreased the release of proangiogenic CXCL8 and increased the release of antiangiogenic CXCL9-11. We conclude that IFNgamma can be released in the presence of native human AML cells and affect AML cell proliferation, regulation of apoptosis and the balance between pro- and antiangiogenic chemokine release.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612597     DOI: 10.1007/s00262-006-0159-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

1.  Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.

Authors:  Sally M Amos; Hollie J Pegram; Jennifer A Westwood; Liza B John; Christel Devaud; Chris J Clarke; Nicholas P Restifo; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Cancer Immunol Immunother       Date:  2011-02-16       Impact factor: 6.968

2.  Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor.

Authors:  Matthew R Lordo; Kevin G Wu; Ekaterina Altynova; Nikolas Shilo; Parker Kronen; Ansel P Nalin; Christoph Weigel; Xiaoli Zhang; Jianhua Yu; Christopher C Oakes; Michael A Caligiuri; Aharon G Freud; Bethany L Mundy-Bosse
Journal:  J Immunol       Date:  2021-08-20       Impact factor: 5.426

Review 3.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

4.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Authors:  Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

5.  Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.

Authors:  Elisabeth Ersvaer; Knut Liseth; Jørn Skavland; Bjørn Tore Gjertsen; Øystein Bruserud
Journal:  BMC Immunol       Date:  2010-07-09       Impact factor: 3.615

6.  Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.

Authors:  Øystein Bruserud; Håkon Reikvam; Hanne Fredly; Jørn Skavland; Karen-Marie Hagen; Tuyen Thy van Hoang; Annette K Brenner; Amir Kadi; Audrey Astori; Bjørn Tore Gjertsen; Frederic Pendino
Journal:  Oncotarget       Date:  2015-02-20

Review 7.  The cytokine network in acute myeloid leukemia.

Authors:  Michela Luciano; Peter W Krenn; Jutta Horejs-Hoeck
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.